Jason Haas Biography and Net Worth

Director of Ligand Pharmaceuticals

Jason Haas has served as a member of the board since June 2022. He is currently the Chief Financial Officer of Odyssey Therapeutics, a clinical-stage biopharmaceutical company. Prior to joining Odyssey, Mr. Haas was the Chief Financial Officer of Syros Pharmaceuticals, a Nasdaq-listed biotech company focused on developing oncology therapeutics, from October 2021 to November 2024. Prior to Syros, Mr. Haas spent over 25 years in healthcare investment banking, where he executed many strategic transactions and supported companies through equity and debt financings, mergers and acquisitions, divestures, and spin-offs. Mr. Haas served as Co-Head of Americas Healthcare Banking at Barclays, Head of Healthcare Investment Banking, Americas at Deutsche Bank and Managing Director of Healthcare Investment Banking at Goldman Sachs. Mr. Haas holds an M.B.A. in Finance from Columbia Business School and an A.B. in International Relations and Economics from Colgate University.

What is Jason Haas' net worth?: The estimated net worth of Jason Haas is at least $1.17 million as of August 12th, 2026. Haas owns 3,981 shares of Ligand Pharmaceuticals stock worth more than $1,168,941 as of August 17th. This net worth evaluation does not reflect any other investments that Haas may own. Learn More about Jason Haas' net worth.
How do I contact Jason Haas?: The corporate mailing address for Haas and other Ligand Pharmaceuticals executives is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. Ligand Pharmaceuticals can also be reached via phone at (858) 550-7500 and via email at [email protected]. Learn More on Jason Haas' contact information.
Has Jason Haas been buying or selling shares of Ligand Pharmaceuticals?: During the last quarter, Jason Haas has sold $2,090,077.78 in Ligand Pharmaceuticals stock. Most recently, Jason Haas sold 7,138 shares of the business's stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $292.81, for a transaction totalling $2,090,077.78. Following the completion of the sale, the director now directly owns 3,981 shares of the company's stock, valued at $1,165,676.61. Learn More on Jason Haas' trading history.
Who are Ligand Pharmaceuticals' active insiders?: Ligand Pharmaceuticals' insider roster includes Todd Davis (CEO), Octavio Espinoza (CFO), Matthew Foehr (COO), Nancy Gray (Director), Jason Haas (Director), John Higgins (CEO), John Kozarich (Director), John LaMattina (Director), Andrew Reardon (Chief Legal Officer), and Stephen Sabba (Director). Learn More on Ligand Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ligand Pharmaceuticals?: During the last year, insiders at the biotechnology company sold shares 30 times. They sold a total of 124,531 shares worth more than $30,657,863.40. The most recent insider tranaction occured on August, 12th when CFO Octavio Espinoza sold 31,641 shares worth more than $9,241,070.46. Insiders at Ligand Pharmaceuticals own 5.6% of the company. Learn More about insider trades at Ligand Pharmaceuticals.
Information on this page was last updated on 8/12/2026.

Jason Haas Insider Trading History at Ligand Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/12/2026	Sell	7,138	$292.81	$2,090,077.78	3,981
6/12/2026	Sell	6,461	$255.58	$1,651,302.38	4,981

Jason Haas Buying and Selling Activity at Ligand Pharmaceuticals

Ligand Pharmaceuticals Company Overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.

Today's Range

Now: $291.77

$291.73

$298.29

50 Day Range

MA: $291.80

$237.75

$322.61

2 Week Range

Now: $291.77

$149.51

$326.63

Volume

145,586 shs

Average Volume

279,592 shs

Market Capitalization

$5.82 billion

P/E Ratio

31.21

Dividend Yield

N/A

Beta

1.13